- Min.Order :100 Gram
- Purity: 99%
- Payment Terms : L/C,D/A,D/P,T/T,Other
Keywords
(–)-1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-di-hydro-1H-indole-7-carboxamide Silodosin API 160970-54-7 supplier
Quick Details
- Appearance:white powder
- Application:pharmaceutical uses
- PackAge:Sealed aluminum foil package
- ProductionCapacity:100|Kilogram|Week
- Storage:Protected from light, stored hermetically and in a dry place
- Transportation:By air or courier or sea
Superiority:
HENAN SUNLAKE ENTERPRISE CORPORATION
Our company advantages:
1、The highest quality with the competitive price.
2、Professional human services.
3、The fastest and safest delivery service.
4、The faster and safest delivery service.
5、The high purity products.
6、We have a sufficient supply of stock.
7、A variety of payments, such as L/C, TT, , MoneyGram or other payments.
Company Information
Henan Sunlake Enterprise Corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion. The com[any was established in june. 1998, until now having more than 18 years experience in manufacturing & exporting chemical raw material .
Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others. These products have been being well exported to europe, southeast Asia, the Middle East ,Africa, South America and some other countries and areas.
We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team. We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional supplier in international market.
We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate with you for a brilliant future!
Details:
Silodosin Basic information
| Treatment of prostatic hyperplasia Benign prostatic hyperplasia Application |
| Product Name: | Silodosin |
| Synonyms: | (–)-1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-di-hydro-1H-indole-7-carboxamide;Silodosin;KAD 3213;KMD 3213;Urief;Silodosin API;Silodosin(Rapaflo);(–)-1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-tr |
| CAS: | 160970-54-7 |
| MF: | C25H32F3N3O4 |
| MW: | 495.53 |
| EINECS: | |
| Product Categories: | Amines;Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;KAD 3213, KMD 3213;Other APIs |
| Mol File: | 160970-54-7.mol |
|
|
|
| Silodosin Chemical Properties |
| CAS DataBase Reference | 160970-54-7(CAS DataBase Reference) |
| Safety Information |
| Silodosin Usage And Synthesis |
| Treatment of prostatic hyperplasia |
Silodosin is a kind of α- adrenergic receptor antagonists developed by Japanese Kissei pharmaceutical company. It has a very good therapeutic efficacy on treating the dysuria related to benign prostatic hyperplasia. The selective effect on urethra of Silodosin is 12 times and 7.4 times as high as that of prazosin and tamsulosin, respectively, which can significantly inhibit norepinephrine-induced contraction of the prostate; it has dose-dependent inhibition bladder activity excitation in the benign prostatic hypertrophy models of rats, and can also improve the pressure threshold of bladder contraction. These data have suggested that, in addition to helping improve bladder function, silodosin is also effective in alleviating the related symptoms associated with benign prostatic hypertrophy. Compared with similar drugs such as prazosin and tamsulosin, silodosin has a high selectivity onn theα1A- receptors located in the prostate and bladder neck, while having a low affinity to theα1B- and α1D-receptor. It can block theα1A- receptors in these sites, and relax the smooth muscle, and thus leading to the improvement of urinary flow rate and the alleviation of BPH symptoms. The selective binding to the α1A-receptor by silodosin has a higher selectivity compared to the binding to the cardiovascular associated receptors α1B, thus maximizing the activity of the target organ as well as minimizing the potential effect on blood pressure. The above information is edited by the chemicalbook of Dai Xiongfeng. |
| Benign prostatic hyperplasia |
Benign prostatic hyperplasia (referred as BPH) is one of the most common diseases in older male with the non-malignant prostate being the character. It can cause the obstructive urination symptoms and other irritation symptoms which have brought significant negative impact on the life of older people. In recent years, with the increasing level of industrialization of China, the annual intake of animal protein intake gradually increased and life expectancy increases, the incidence of benign prostatic hyperplasia also has increased year by year. Over 50 percent in elderly people at age 60 or above has got this disease. This ratio increases to over 90% for elderly people over 85 years-old. Its triggering factor has not been totally elucidated. It is generally believed that this is related to the secretion of sex hormones and cholesterol as well as other kinds of metabolic disorders. Some people think that, for elder people, their weakened pituitary- gonadotropin-pathway or endogenous change cause degeneration of testicles decreased sexual function, reduced testosterone value, as well as the change of glandular epithelium and enlarged prostate caused by the increased connected tissue of prostate. The enlargement of prostate will compress the urethra, resulting in poor urine flow of bladder and even blocked bladder outlet. There is α1A- adrenergic receptor located in the human prostate. The activation of the receptor will deteriorate the symptoms of dysuria and urethral obstruction. Therefore, by blocking the binding α1A- adrenergic receptor, we can relax the obstructed prostate smooth muscle relaxation, and thereby alleviating the symptoms. In recent years, people has achieved excellent efficacy by clinically applying 5α- reductase inhibitors and α1- adrenergic receptors (α1-AR) blocker (silodosin). This is considered as a major breakthrough in drug treatment of benign prostatic hyperplasia. |
| Application | It can be used for treatment of benign prostatic hyperplasia. |
| Chemical Properties | White Solid |
| Usage | An α1a-adrenoceptor antagonist. It is used in treatment of benign prostatic hypertophy. |
| Usage | Silodosin(Rapaflo) is an α1-adrenoceptor antagonist with high uroselectivity. It causes practically no orthostatic hypotension (in contrast to other α1 blockers). Since Silodosin is a highly selective inhibitor of the α1A adrenergic receptor, it causes pr |
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View